Ultragenyx Pharmaceutical (RARE) Change in Account Payables (2013 - 2019)
Ultragenyx Pharmaceutical (RARE) posted quarterly Change in Account Payables of $3.9 million for Q3 2019, up 298.58% year-over-year from $980987.5 in Q3 2018, and up 211.94% quarter-over-quarter from -$3.5 million in Q2 2019.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Change in Account Payables (2013 - 2019) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Change in Account Payables for 7 consecutive years, with $3.9 million the latest figure, recorded in Q3 2019.
- In Q3 2019, Change in Account Payables rose 298.58% year-over-year to $3.9 million; the TTM figure through Sep 2019 stood at $4.2 million (up 517.67% YoY), while the FY2018 annual figure was $3.4 million, down 2.52% from the prior year.
- Change in Account Payables rose to $3.9 million in Q3 2019 per RARE's latest filing, from -$3.5 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.3 million in Q2 2015 and bottomed at -$5.3 million in Q3 2015.
- Historically, Change in Account Payables has averaged $400894.7 across 5 years, with a median of $187000.0 in 2016.
- On a YoY basis, Change in Account Payables climbed as much as 4528.57% in 2015 and fell as far as 825.92% in 2015.
- Ultragenyx Pharmaceutical's Change in Account Payables stood at -$1.4 million in 2015, then grew by 6.82% to -$1.3 million in 2016, then jumped by 68.66% to -$420000.0 in 2017, then jumped by 1044.05% to $4.0 million in 2018, then decreased by 1.39% to $3.9 million in 2019.
- Business Quant data shows RARE's Change in Account Payables at $3.9 million in Q3 2019, -$3.5 million in Q2 2019, and -$151000.0 in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 3.91 Mn |
| Jun 30, 2019 | -3.49 Mn |
| Mar 31, 2019 | -151,000.00 |
| Dec 31, 2018 | 3.97 Mn |
| Sep 30, 2018 | -1.97 Mn |
| Jun 30, 2018 | 2.69 Mn |
| Mar 31, 2018 | -1.32 Mn |
| Dec 31, 2017 | -420,000.00 |
| Sep 30, 2017 | -2.47 Mn |
| Jun 30, 2017 | 3.36 Mn |
| Mar 31, 2017 | 2.99 Mn |
| Dec 31, 2016 | -1.34 Mn |
| Sep 30, 2016 | 1.02 Mn |
| Jun 30, 2016 | 187,000.00 |
| Mar 31, 2016 | 2.64 Mn |
| Dec 31, 2015 | -1.44 Mn |
| Sep 30, 2015 | -5.32 Mn |
| Jun 30, 2015 | 4.34 Mn |
| Mar 31, 2015 | 437,000.00 |
| Dec 31, 2014 | 484,000.00 |